0001567619-22-009865.txt : 20220509
0001567619-22-009865.hdr.sgml : 20220509
20220509212946
ACCESSION NUMBER: 0001567619-22-009865
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220429
FILED AS OF DATE: 20220509
DATE AS OF CHANGE: 20220509
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES
CENTRAL INDEX KEY: 0001221590
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26727
FILM NUMBER: 22907074
MAIL ADDRESS:
STREET 1: 925 PAGE MILL ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC
CENTRAL INDEX KEY: 0001048477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 680397820
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 4155066700
MAIL ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
doc1.xml
FORM 4
X0306
4
2022-04-29
0
0001048477
BIOMARIN PHARMACEUTICAL INC
BMRN
0001221590
BIENAIME JEAN JACQUES
C/O BIOMARIN PHARMACEUTICAL INC.
770 LINDARO ST.
SAN RAFAEL
CA
94901
1
1
0
0
Chief Executive Officer
Common Stock
2022-04-29
5
A
0
341
62.407
A
335324
D
Common Stock
2022-05-05
4
M
0
10000
37.46
A
345324
D
Common Stock
2022-05-05
4
S
0
10000
84.14
D
335324
D
Common Stock
2022-05-06
4
M
0
20000
37.46
A
355324
D
Common Stock
2022-05-06
4
S
0
20000
81.00
D
335324
D
Common Stock
247533
I
Shares held by Jean-Jacques Bienaime Family Trust
Stock Option (Right to buy Common Stock)
37.46
2022-05-05
4
M
0
10000
0
D
2012-11-08
2022-05-07
Common Stock
10000
20000
D
Stock Option (Right to buy Common Stock)
37.46
2022-05-06
4
M
0
20000
0
D
2012-11-08
2022-05-07
Common Stock
20000
0
D
Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan.
Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022.
Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Mr. Bienaime's former spouse will receive approximately 73% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime.
Reflects the number of options outstanding after the transactions from this specific stock option grant.
/s/ Laura Randall Woodhead, Attorney-in-Fact
2022-05-09